Both Zovirax and Abreva offer similar effectiveness in symptom control, with the main difference being how quickly they act. Either drug is a viable option depending on the patient’s needs.

Both Zovirax and Abreva have similar safety profiles, with mild and transient side effects. Neither presents significant long-term safety concerns.

Both Zovirax and Abreva have a low risk of addiction when used correctly under medical supervision, with minimal potential for misuse.

Both Zovirax and Abreva are easy to use, with straightforward dosing regimens that ensure good adherence.

Zovirax has fewer contraindications, making it suitable for a broader range of patients, including those with comorbidities.

Both drugs offer advantages depending on treatment goals. Zovirax is great for fast relief, while Abreva is better for long-term management. The choice depends on the patient’s specific needs.